{"pmid":32096395,"title":"[The treatment proposal for the patients with breast diseases in the central epidemic area of 2019 coronavirus disease].","text":["[The treatment proposal for the patients with breast diseases in the central epidemic area of 2019 coronavirus disease].","Currently, the epidemic of 2019 coronavirus disease (COVID-19) is still ongoing. The characteristics including high contagiousness, herd susceptibility and clinical phenotype diversity, made a serious influence on people's daily life and rountine therapy for other diseases. Breast dieases are clinical common diseases. In the central epidemic area of COVID-19, Hubei province, especially Wuhan, the clinical specialists of breast diseases should consider all of the following factors comprehensively: the prevention of COVID-19, the diagnosis and treatment of breast diseases and the accessibility of medical resources. Besides, we should select the appropriate therapy and optimize treatment process so as to prevent the propagation and cross infection of COVID-19 as well as manage the breast diseases without delay. Therefore, we carried out some management proposals of the patients with breast diseases in the central epidemic area during the epidemic of COVID-19 on the basis of conventional treatment guidelines and clinical experiences. The suggestions and corrections from colleagues will be welcomed.","Zhonghua Wai Ke Za Zhi","Zhao, L","Zhang, L","Liu, J W","Yang, Z F","Shen, W Z","Li, X R","32096395"],"abstract":["Currently, the epidemic of 2019 coronavirus disease (COVID-19) is still ongoing. The characteristics including high contagiousness, herd susceptibility and clinical phenotype diversity, made a serious influence on people's daily life and rountine therapy for other diseases. Breast dieases are clinical common diseases. In the central epidemic area of COVID-19, Hubei province, especially Wuhan, the clinical specialists of breast diseases should consider all of the following factors comprehensively: the prevention of COVID-19, the diagnosis and treatment of breast diseases and the accessibility of medical resources. Besides, we should select the appropriate therapy and optimize treatment process so as to prevent the propagation and cross infection of COVID-19 as well as manage the breast diseases without delay. Therefore, we carried out some management proposals of the patients with breast diseases in the central epidemic area during the epidemic of COVID-19 on the basis of conventional treatment guidelines and clinical experiences. The suggestions and corrections from colleagues will be welcomed."],"journal":"Zhonghua Wai Ke Za Zhi","authors":["Zhao, L","Zhang, L","Liu, J W","Yang, Z F","Shen, W Z","Li, X R"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32096395","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112139-20200221-00116","keywords":["Breast diseases","COVID-19","Coronavirus infected diseases","Novel coronavirus pneumonia"],"source":"PubMed","locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647440764928,"score":6.7365713,"similar":[{"pmid":32100979,"title":"[Health management of breast cancer patients outside the hospital during the outbreak of 2019 novel coronavirus disease].","text":["[Health management of breast cancer patients outside the hospital during the outbreak of 2019 novel coronavirus disease].","The outbreak of 2019 novel coronavirus disease (COVID-19) is spreading rapidly. In order to prevent cluster outbreaks, the government strengthened the management and control of personnel mobility, which had a great impact on the examination and treatment of breast cancer patients. This paper discusses how to realize scientific health management of breast cancer patients outside the hospital based on the existing epidemic situation, characteristics of breast cancer patients and public health safety factors. The breast cancer patients should synthetically consider the epidemic prevention situation of inhabitance, the disease stage and previous therapeutic schedule to decide the next therapeutic schedule. If necessary, after professional discussion and communication between doctors and patients online or offline, the hospital visiting time should be delayed through seeking alternative treatment schemes, and psychological counseling for patients should be paid attention to at the same time.","Zhonghua Zhong Liu Za Zhi","Liu, B L","Ma, F","Wang, J N","Fan, Y","Mo, H N","Xu, B H","32100979"],"abstract":["The outbreak of 2019 novel coronavirus disease (COVID-19) is spreading rapidly. In order to prevent cluster outbreaks, the government strengthened the management and control of personnel mobility, which had a great impact on the examination and treatment of breast cancer patients. This paper discusses how to realize scientific health management of breast cancer patients outside the hospital based on the existing epidemic situation, characteristics of breast cancer patients and public health safety factors. The breast cancer patients should synthetically consider the epidemic prevention situation of inhabitance, the disease stage and previous therapeutic schedule to decide the next therapeutic schedule. If necessary, after professional discussion and communication between doctors and patients online or offline, the hospital visiting time should be delayed through seeking alternative treatment schemes, and psychological counseling for patients should be paid attention to at the same time."],"journal":"Zhonghua Zhong Liu Za Zhi","authors":["Liu, B L","Ma, F","Wang, J N","Fan, Y","Mo, H N","Xu, B H"],"date":"2020-02-27T11:00:00Z","year":2020,"_id":"32100979","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112152-20200221-00110","keywords":["2019 novel coronavirus disease","Breast neoplasms","Health management outside the hospital"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647464882176,"score":355.29492},{"pmid":32108459,"title":"[Treatment strategies of Budd-Chiari syndrome during the epidemic period of 2019 coronavirus disease].","text":["[Treatment strategies of Budd-Chiari syndrome during the epidemic period of 2019 coronavirus disease].","Prevention and control about the situation of 2019 coronavirus disease (COVID-19) are grim at present. In addition to supporting the frontline actively, medical workers in general surgery spare no efforts in making good diagnosis and treatment of specialized diseases by optimizing treatment process, providing medical advice online, mastering indications of delayed operation and emergency operation reasonably, etc. Budd-Chiari syndrome is a complex disorder, and severity of the disease varies, serious cases can be life threatening. While fighting the epidemic, medical workers should also ensure the medical needs of patients. However, instead of continuing the traditional treatment, a new management system should be developed. Based on the characteristics of Budd-Chiari syndrome patients in China and our experience, we divide the patients into ordinary and critical cases, and treatment strategies suitable for the epidemic period of COVID-19 are put forward for reference and discussion by physicians.","Zhonghua Wai Ke Za Zhi","Li, L H","Zhang, G","Dang, X W","Li, L","32108459"],"abstract":["Prevention and control about the situation of 2019 coronavirus disease (COVID-19) are grim at present. In addition to supporting the frontline actively, medical workers in general surgery spare no efforts in making good diagnosis and treatment of specialized diseases by optimizing treatment process, providing medical advice online, mastering indications of delayed operation and emergency operation reasonably, etc. Budd-Chiari syndrome is a complex disorder, and severity of the disease varies, serious cases can be life threatening. While fighting the epidemic, medical workers should also ensure the medical needs of patients. However, instead of continuing the traditional treatment, a new management system should be developed. Based on the characteristics of Budd-Chiari syndrome patients in China and our experience, we divide the patients into ordinary and critical cases, and treatment strategies suitable for the epidemic period of COVID-19 are put forward for reference and discussion by physicians."],"journal":"Zhonghua Wai Ke Za Zhi","authors":["Li, L H","Zhang, G","Dang, X W","Li, L"],"date":"2020-02-29T11:00:00Z","year":2020,"_id":"32108459","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112139-20200221-00109","keywords":["2019 coronavirus disease","Budd-Chiari syndrome","Coronavirus infections","Critical cases","Novel coronavirus pneumonia"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647506825216,"score":188.81224},{"pmid":32111113,"title":"[The keypoints in treatment of the critical coronavirus disease 2019 patient].","text":["[The keypoints in treatment of the critical coronavirus disease 2019 patient].","The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated.","Zhonghua Jie He He Hu Xi Za Zhi","Li, X Y","Du, B","Wang, Y S","Kang, H Y J","Wang, F","Sun, B","Qiu, H B","Tong, Z H","32111113"],"abstract":["The treatment of critically ill patients with coronavirus disease 2019(COVID-19) faces compelling challenges. In this issue, we'd like to share our first-line treatment experience in treating COVID-19. Hemodynamics need be closely monitored and different types of shock should be distinguished. Vasoconstrictor drugs should be used rationally and alerting of complications is of the same importance. The risk of venous thromboembolism (VTE) needs to be assessed, and effective prevention should be carried out for high-risk patients. It is necessary to consider the possibility of pulmonary thromboembolism (PTE) in patients with sudden onset of oxygenation deterioration, respiratory distress, reduced blood pressure. However, comprehensive analysis of disease state should be taken into the interpretation of abnormally elevated D-Dimer. Nutritional support is the basis of treatment. It's important to establish individual therapy regimens and to evaluate, monitor and adjust dynamically. Under the current epidemic situation, convalescent plasma can only be used empirically, indications need to be strictly screened, the blood transfusion process should be closely monitored and the curative effect should be dynamically evaluated."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Li, X Y","Du, B","Wang, Y S","Kang, H Y J","Wang, F","Sun, B","Qiu, H B","Tong, Z H"],"date":"2020-03-01T11:00:00Z","year":2020,"_id":"32111113","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112147-20200224-00159","keywords":["Convalescent plasma","Coronavirus disease 2019, COVID-19","Nutritional support","Vasoconstrictor drugs","Venous thromboembolism"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647975538688,"score":142.3428},{"pmid":32174096,"title":"[Management strategies for patients with gynecological malignancies during the outbreak of COVID19].","text":["[Management strategies for patients with gynecological malignancies during the outbreak of COVID19].","Objective: To explore the management strategies for patients with gynecological malignant tumors during the outbreak and transmission of COVID19. Methods: We retrospectively analyzed the clinical characteristics, treatment, and disease outcomes of three patients with gynecological malignancies associated with COVID19 in Renmin Hospital of Wuhan University in January 2020, and proposed management strategies for patients with gynecological tumors under risk of COVID19. Results: Three patients were treated COVID19 based on the national diagnosis and treatment protocol as well as research progress. Meanwhile, these patients were appropriately adjusted the treatment plan in accordance with the clinical guidelines for gynecological tumors. Pneumonia was cured in 2 patients, and one patient died of COVID-19. Conclusions: Patients with gynecological malignant tumors are high-risk groups prone to COVID-19 infection, and gynecological oncologists need to carry out education, prevention, control and treatment according to specific conditions. While actively preventing and controlling COVID-19, the diagnosis and treatment of gynecological malignant tumors should be carried out in an orderly and safe manner.","Zhonghua Fu Chan Ke Za Zhi","Zhang, J","Peng, P","Li, X","Zha, Y F","Zhang, G N","Zhang, Y","Xiang, Y","32174096"],"abstract":["Objective: To explore the management strategies for patients with gynecological malignant tumors during the outbreak and transmission of COVID19. Methods: We retrospectively analyzed the clinical characteristics, treatment, and disease outcomes of three patients with gynecological malignancies associated with COVID19 in Renmin Hospital of Wuhan University in January 2020, and proposed management strategies for patients with gynecological tumors under risk of COVID19. Results: Three patients were treated COVID19 based on the national diagnosis and treatment protocol as well as research progress. Meanwhile, these patients were appropriately adjusted the treatment plan in accordance with the clinical guidelines for gynecological tumors. Pneumonia was cured in 2 patients, and one patient died of COVID-19. Conclusions: Patients with gynecological malignant tumors are high-risk groups prone to COVID-19 infection, and gynecological oncologists need to carry out education, prevention, control and treatment according to specific conditions. While actively preventing and controlling COVID-19, the diagnosis and treatment of gynecological malignant tumors should be carried out in an orderly and safe manner."],"journal":"Zhonghua Fu Chan Ke Za Zhi","authors":["Zhang, J","Peng, P","Li, X","Zha, Y F","Zhang, G N","Zhang, Y","Xiang, Y"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174096","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn112141-20200302-00168","keywords":["COVID-19","Gynecological malignancies","Management strategy"],"source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1661456248843796480,"score":139.32523},{"pmid":32118391,"title":"[Cause analysis and treatment strategies of \"recurrence\" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital].","text":["[Cause analysis and treatment strategies of \"recurrence\" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital].","With a large number of COVID-19 patients discharging from hospital, some had showed re-fever and positive nucleic acid test after discharge from hospital. This might be due to the biological characteristics of 2019-nCoV, and might also be related to the basic disease, clinical status, glucocorticoid using, sample sampling, processing and detecting of patients, and some even related to the re-infection or secondary bacterial virus infection. Therefore, we suggest that in view of this phenomenon, further stratified management of discharge from hospital should be carried out on the basis of guidelines, especially for patients with advanced age, underlying diseases or severe or critical pneumonia. For those patients who can't completely deoxygenate for a long time after hospitalization, individualized treatment methods and different discharge evaluation criteria should be adopted to ensure the complete cure of patients and prevent recurrencing after discharge from hospital.","Zhonghua Jie He He Hu Xi Za Zhi","Zhou, L","Liu, K","Liu, H G","32118391"],"abstract":["With a large number of COVID-19 patients discharging from hospital, some had showed re-fever and positive nucleic acid test after discharge from hospital. This might be due to the biological characteristics of 2019-nCoV, and might also be related to the basic disease, clinical status, glucocorticoid using, sample sampling, processing and detecting of patients, and some even related to the re-infection or secondary bacterial virus infection. Therefore, we suggest that in view of this phenomenon, further stratified management of discharge from hospital should be carried out on the basis of guidelines, especially for patients with advanced age, underlying diseases or severe or critical pneumonia. For those patients who can't completely deoxygenate for a long time after hospitalization, individualized treatment methods and different discharge evaluation criteria should be adopted to ensure the complete cure of patients and prevent recurrencing after discharge from hospital."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","authors":["Zhou, L","Liu, K","Liu, H G"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32118391","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200229-00219","keywords":["COVID-19","Cause analysis","Discharge from hospital","Recurrence","Treatment strategies"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1661359647595954176,"score":135.0654}]}